Repligen ( (RGEN) ) has released its Q4 earnings. Here is a breakdown of the information Repligen presented to its investors.
Discover the Best Stocks and Maximize Your Portfolio:
- See what stocks are receiving strong buy ratings from top-rated analysts.
- Filter, analyze, and streamline your search for investment opportunities with TipRanks’ Stock Screener.
Repligen Corporation is a global life sciences company specializing in bioprocessing technologies and systems that enhance the manufacturing efficiencies of biological drugs, serving primarily biopharmaceutical companies and contract development and manufacturing organizations worldwide. The company, headquartered in Waltham, Massachusetts, operates manufacturing sites across the U.S. and Europe.
Repligen announced its financial results for the fourth quarter and full year of 2024, highlighting a revenue increase to $168 million for the quarter and $634 million for the year. The company also provided guidance for the full year 2025, anticipating reported growth between 8% and 12%, excluding COVID-related revenue.
Key financial highlights include a sequential increase in fourth-quarter orders and revenues by 11% and 8%, respectively, with orders exceeding sales by 6%. The company closed the acquisition of Tantti Laboratory Inc., expanding its chromatography offerings, and launched the AVIPure® dsRNA resin. Despite a GAAP net loss of $34 million for Q4, adjusted net income was reported at $25 million, reflecting restructuring and inventory charges.
Looking ahead, Repligen’s management remains optimistic about the bioprocessing market’s return to growth, driven by strong order momentum. The company aims to achieve its 2025 guidance while continuing to monitor developments in China and emerging biotech markets.
